See more : Beyond, Inc. (0KDU.L) Income Statement Analysis – Financial Results
Complete financial analysis of Zynerba Pharmaceuticals, Inc. (ZYNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zynerba Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Aberforth Split Level Income ZDP 2024 (ASIZ.L) Income Statement Analysis – Financial Results
- Aspen Insurance Holdings Limited (AHL-PD) Income Statement Analysis – Financial Results
- GME Group Holdings Limited (8188.HK) Income Statement Analysis – Financial Results
- Concord Biotech Limited (CONCORDBIO.NS) Income Statement Analysis – Financial Results
- Verde Clean Fuels, Inc. (VGAS) Income Statement Analysis – Financial Results
Zynerba Pharmaceuticals, Inc. (ZYNE)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zynerba.com
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 7.25K | 7.25K | 278.90K | 810.01K | 943.90K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 7.25K | 7.25K | 278.90K | 810.01K | 943.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 21.10M | 21.42M | 35.65M | 20.38M | 27.25M | 22.81M | 16.78M | 7.45M | 2.40M | 1.13M |
| General & Administrative | 14.15M | 15.35M | 16.41M | 13.94M | 13.24M | 10.02M | 6.43M | 5.36M | 4.08M | 444.30K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.15M | 15.35M | 16.41M | 13.94M | 13.24M | 10.02M | 6.43M | 5.36M | 4.08M | 444.30K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.25M | 36.77M | 52.06M | 34.32M | 40.48M | 32.82M | 23.21M | 12.81M | 6.48M | 1.58M |
| Cost & Expenses | 35.25M | 36.77M | 52.06M | 34.32M | 40.48M | 32.82M | 23.21M | 12.81M | 6.48M | 1.58M |
| Interest Income | 846.86K | 21.05K | 243.99K | 1.52M | 961.32K | 519.55K | 80.22K | 0.00 | 0.00 | 0.00 |
| Interest Expense | -215.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 631.13K | 559.68K | -481.72K | 145.91K | 99.57K | 94.21K | 75.30K | 26.03K | 27.06K | 49.39K |
| EBITDA | -34.62M | -36.21M | -52.06M | -34.17M | -40.40M | -32.82M | -23.21M | -12.51M | -5.64M | -585.05K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,422.28% | -456,747.03% | -316,123.92% | -4,483.73% | -696.37% | -61.98% |
| Operating Income | -35.25M | -36.77M | -52.06M | -34.32M | -40.40M | -32.82M | -23.21M | -12.53M | -5.67M | -634.44K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,974.22% | -452,731.16% | -320,105.21% | -4,493.07% | -699.71% | -67.21% |
| Total Other Income/Expenses | 215.73K | -538.63K | 725.71K | 1.38M | 486.66K | 810.71K | -208.42K | 7.35K | -1.84K | -2.35K |
| Income Before Tax | -35.04M | -37.31M | -51.34M | -32.94M | -39.91M | -32.01M | -23.42M | -12.52M | -5.67M | -636.79K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,408.34% | -441,549.02% | -322,980.00% | -4,490.43% | -699.94% | -67.46% |
| Income Tax Expense | -215.73K | 291.49K | -932.75K | -1.51M | 486.66K | -27.54K | -27.54K | 27.54K | 0.00 | 0.00 |
| Net Income | -34.82M | -37.60M | -50.40M | -31.43M | -39.91M | -32.01M | -23.39M | -12.55M | -5.67M | -636.79K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,408.34% | -441,549.02% | -322,600.10% | -4,500.30% | -699.94% | -67.46% |
| EPS | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| EPS Diluted | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| Weighted Avg Shares Out | 42.66M | 39.26M | 27.02M | 22.00M | 15.31M | 12.91M | 9.07M | 4.46M | 5.73M | 5.73M |
| Weighted Avg Shares Out (Dil) | 42.66M | 39.26M | 27.02M | 22.00M | 15.31M | 12.91M | 9.07M | 4.46M | 5.73M | 5.73M |
Zynerba ends 1Q with strong $69.7M cash runway to advance its novel Zygel CBD Gel for Fragile X Syndrome
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has reported results for the first quarter that reveal ample cash on hand, giving the company scope to run pivotal trials of its flagship product Zygel (ZYN002). As of March 31, 2022, the Devon, Pennsylvania-based company...
Zynerba presents positive data on Zygel in children and adolescents with Fragile X Syndrome at International Society for Autism Research meeting
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc, a leader in transdermal cannabinoid therapies for rare neuropsychiatric disorders, revealed that it is making an oral podium presentation at the International Society for Autism Research's four-day annual meeting starting on May 11, 2022. The meeting...
Zynerba Pharmaceuticals announces presentation of poster on Zygel at the 2022 Society of Biological Psychiatry Annual Meeting
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc said it presented a poster on the long-term safety and efficacy of its cannabidiol transdermal gel, Zygel, at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting held in New Orleans, Louisiana, and virtually, from April...
Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
DEVON, Pa., April 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will present a...
Cannabis Sector Kicks Off March With a Blast of Q4 Earnings
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks, and look at how the cannabis industry is evolving as we make our way through 2022.
Canaccord Genuity calls Zynerba "undervalued," reiterates Buy rating after positive 4Q results
Canaccord Genuity (TSX:CF, LSE:CF) said it continued to believe that Zynerba Pharmaceuticals (NASDAQ:ZYNE) is undervalued after the company reported its fourth-quarter financial results that showed a $67.8 million cash runway to advance its flagship Zygel CBD Gel for Fragile X Syndrome....
Zynerba ends 4Q flush with $67.8M cash runway to advance its flagship Zygel CBD Gel for Fragile X Syndrome
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc's results for the fourth quarter and full year reveal ample cash on hand, giving the company scope to run pivotal trials of its flagship product Zygel (ZYN002). In the financial year ended December 31, 2021, the Devon,...
Zynerba Pharmaceuticals appoints Albert Parker as its new chief legal officer upon retirement of Suzanne Hanlon at end-February
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has announced the appointment of Albert P Parker as the company's new chief legal officer and corporate secretary. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, will assume the...
Zynerba Pharmaceuticals Names New CLO & Corporate Secretary
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal officer and corporate secretary.
Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has decided not to advance Zygel against developmental and epileptic encephalopathies (DEE). The decision was in line with the feedback from the FDA, which indicated that the selection of a specific DEE syndrome would be required to support...
Source: https://incomestatements.info
Category: Stock Reports